Based on this rationale, this study might also be helpful for the selection of osteosarcoma patients that could potentially benefit from anti-PARP therapy, especially those in the poor-prognostic subgroup of osteosarcomas expressing PARP1, γH2AX, or BRCA1/2. Here, PARP1 is linked to osteosarcoma.